Last reviewed · How we verify
AS-101
At a glance
| Generic name | AS-101 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC) (PHASE1)
- Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) (PHASE1, PHASE2)
- Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts (PHASE2)
- Topical Application of AS101 for the Treatment of Psoriasis (PHASE2)
- Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (PHASE2)
- Topical Application of AS101 for the Treatment of Atopic Dermatitis (PHASE2)
- Safety and Efficacy Study to Test Topical AS101 for External Genital Warts (PHASE1, PHASE2)
- Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AS-101 CI brief — competitive landscape report
- AS-101 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI